Recent Updates
Recently added Catalysts
PFE Positive Sentiment Score: 85/100

European Commission Authorizes Pfizer and BioNTech XFG-adapted COVID-19 Vaccine in the European Union

Wednesday, July 29, 2026 1 min read
Key Takeaway: Pfizer and BioNTech have received marketing authorization from the European Commission for their COVID-19 vaccine targeting the XFG variant. This new formulation is approved for active immunization in individuals aged 6 months and older. The authorization follows recommendations from the European Medicines Agency's Emergency Task Force.

Market Sentiment Analysis

POSITIVE FACTORS

  • European Commission grants marketing authorization.
  • New vaccine targets the XFG variant.
  • Vaccine approved for individuals 6 months and older.
  • Collaboration between Pfizer and BioNTech continues to evolve.

Full Press Release Details

NEW YORK & MAINZ, Germany--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Commission (EC) has granted marketing authorization for the companies’ 2026-2027 COVID-19 vaccine formula, targeting the XFG variant, for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the Emergency Task Force (ETF) of the European Medic

Frequently Asked Questions

What vaccine was authorized by the European Commission?

The European Commission authorized the Pfizer and BioNTech XFG-adapted COVID-19 vaccine.

Who is eligible for the new COVID-19 vaccine?

The vaccine is approved for individuals aged 6 months and older.

What variant does the new vaccine target?

The vaccine targets the XFG variant of the SARS-CoV-2 virus.

What organization recommended the vaccine adaptation?

The adaptation was based on recommendations from the European Medicines Agency's Emergency Task Force.

Tags: PFE Viatris Investor Conferences Healthcare Pfizer BioNTech COVID-19 vaccine XFG variant European Commission
Last updated: Jul 29, 2026

Biotech snapshot

Cash runway
$9892M liquidity · $0M/mo burn
Low dilution risk
Lead asset
EpogenPhase 3
Chronic Kidney Disease →

Catalyst track record

+27%
best trade around PFE's last catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for PFE.

See every catalyst's timing & PoA →